Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735

Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi J. Mclntyre, John E. Pippen, James H. Bordelon, Robert L. Kirby, John Sandbach, William J. Hyman, Donald A. Richards, Robert G. Mennel, Kristi A. Boehm, Wally G. Meyer, Lina Asmar, Daniel Mackey, Stefan Riedel, Hyman Muss, Michael A. Savin

Research output: Contribution to journalArticle

390 Citations (Scopus)

Abstract

Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.

Original languageEnglish (US)
Pages (from-to)1177-1183
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number8
DOIs
StatePublished - Mar 10 2009
Externally publishedYes

Fingerprint

docetaxel
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Survival
Research
TC 81
Hormones
Febrile Neutropenia
Adjuvant Chemotherapy
Intravenous Infusions
Anemia
Lymph Nodes
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of us oncology research trial 9735. / Jones, Stephen; Holmes, Frankie Ann; O'Shaughnessy, Joyce; Blum, Joanne L.; Vukelja, Svetislava J.; Mclntyre, Kristi J.; Pippen, John E.; Bordelon, James H.; Kirby, Robert L.; Sandbach, John; Hyman, William J.; Richards, Donald A.; Mennel, Robert G.; Boehm, Kristi A.; Meyer, Wally G.; Asmar, Lina; Mackey, Daniel; Riedel, Stefan; Muss, Hyman; Savin, Michael A.

In: Journal of Clinical Oncology, Vol. 27, No. 8, 10.03.2009, p. 1177-1183.

Research output: Contribution to journalArticle

Jones, S, Holmes, FA, O'Shaughnessy, J, Blum, JL, Vukelja, SJ, Mclntyre, KJ, Pippen, JE, Bordelon, JH, Kirby, RL, Sandbach, J, Hyman, WJ, Richards, DA, Mennel, RG, Boehm, KA, Meyer, WG, Asmar, L, Mackey, D, Riedel, S, Muss, H & Savin, MA 2009, 'Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735', Journal of Clinical Oncology, vol. 27, no. 8, pp. 1177-1183. https://doi.org/10.1200/JCO.2008.18.4028
Jones, Stephen ; Holmes, Frankie Ann ; O'Shaughnessy, Joyce ; Blum, Joanne L. ; Vukelja, Svetislava J. ; Mclntyre, Kristi J. ; Pippen, John E. ; Bordelon, James H. ; Kirby, Robert L. ; Sandbach, John ; Hyman, William J. ; Richards, Donald A. ; Mennel, Robert G. ; Boehm, Kristi A. ; Meyer, Wally G. ; Asmar, Lina ; Mackey, Daniel ; Riedel, Stefan ; Muss, Hyman ; Savin, Michael A. / Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of us oncology research trial 9735. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 8. pp. 1177-1183.
@article{c39794b8798447a0ab8506962a076767,
title = "Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735",
abstract = "Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16{\%} of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 {\%} TC v 75{\%} AC; P =.033; hazard ratio [HR], 0.74; 95{\%} CI 0.56 to 0.98) as was OS (87{\%} TC v 82{\%} AC; P =.032; HR, 0.69; 95{\%} CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.",
author = "Stephen Jones and Holmes, {Frankie Ann} and Joyce O'Shaughnessy and Blum, {Joanne L.} and Vukelja, {Svetislava J.} and Mclntyre, {Kristi J.} and Pippen, {John E.} and Bordelon, {James H.} and Kirby, {Robert L.} and John Sandbach and Hyman, {William J.} and Richards, {Donald A.} and Mennel, {Robert G.} and Boehm, {Kristi A.} and Meyer, {Wally G.} and Lina Asmar and Daniel Mackey and Stefan Riedel and Hyman Muss and Savin, {Michael A.}",
year = "2009",
month = "3",
day = "10",
doi = "10.1200/JCO.2008.18.4028",
language = "English (US)",
volume = "27",
pages = "1177--1183",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide

T2 - 7-year follow-up of us oncology research trial 9735

AU - Jones, Stephen

AU - Holmes, Frankie Ann

AU - O'Shaughnessy, Joyce

AU - Blum, Joanne L.

AU - Vukelja, Svetislava J.

AU - Mclntyre, Kristi J.

AU - Pippen, John E.

AU - Bordelon, James H.

AU - Kirby, Robert L.

AU - Sandbach, John

AU - Hyman, William J.

AU - Richards, Donald A.

AU - Mennel, Robert G.

AU - Boehm, Kristi A.

AU - Meyer, Wally G.

AU - Asmar, Lina

AU - Mackey, Daniel

AU - Riedel, Stefan

AU - Muss, Hyman

AU - Savin, Michael A.

PY - 2009/3/10

Y1 - 2009/3/10

N2 - Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.

AB - Purpose We previously reported that four cycles of docetaxel/ cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of doxorubicin/cyclophosphamide (AC) in early breast cancer. Older women are under-represented in adjuvant chemotherapy trials. In our trial 16% of patients were ≥ 65 years. We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HEH2 status on outcome and toxicity. Patients and Methods Patients were randomly assigned to receive either four cycles of standard-dose AC (60/600 mg/m2; n = 510), or TC (75/600 mg/m2; n = 506), administered by intravenous infusion every 3 weeks. Results The median age in women younger than 65, was 50 years (range, 27 to 64) and for women ≥ 65 was 69 years (range, 65 to 77). Baseline characteristics in the two age subgroups were generally well matched, except that older women tended to have more lymph node involvement. At a median of 7 years follow-up, the difference in DFS between TC and AC was significant (81 % TC v 75% AC; P =.033; hazard ratio [HR], 0.74; 95% CI 0.56 to 0.98) as was OS (87% TC v 82% AC; P =.032; HR, 0.69; 95% CI, 0.50 to 0.97). TC was superior in older patients as well as younger patients. There was no interaction of hormone-receptor status or HER-2 status and treatment. Older women experienced more febrile neutropenia with TC and more anemia with AC. Conclusion With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.

UR - http://www.scopus.com/inward/record.url?scp=62449193617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449193617&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.18.4028

DO - 10.1200/JCO.2008.18.4028

M3 - Article

C2 - 19204201

AN - SCOPUS:62449193617

VL - 27

SP - 1177

EP - 1183

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -